drugset
Drugs / AVZO-1418
last change 23 days ago re-read 3 minutes ago

AVZO-1418

Developed for
biliary tract cancer · lung cancer · metastatic neoplasm · nasopharyngeal neoplasm · urothelial carcinoma
Investigated by
Avenzo Therapeutics, Inc.

Trials 1

today NCT07038343 · Ph 1/2
20262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07038343 Jun 2025 → Jun 2030 expected biliary tract cancer, lung cancer, metastatic neoplasm, nasopharyngeal neoplasm +1 Avenzo Therapeutics, Inc. Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2025-11-10 DualityBio Inc. Regulatory Fast Track Designation Granted for AVZO-1418/DB-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC dualitybiologics.com ↗
2025-11-10 Avenzo Therapeutics, Inc. Regulatory Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC avenzotx.com ↗
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AVZO-1418 (DB-1418), a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate (BsADC).
2025-05-22 DualityBio Inc. Regulatory FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 dualitybiologics.com ↗
2025-05-22 Avenzo Therapeutics, Inc. Regulatory Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate avenzotx.com ↗
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

All press releases naming this drug 9 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AVZO-1418 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07038343 ↗
Route Intravenous “AVZO-1418 when administered intravenously” NCT07038343 ↗